Virological Tools Fail to Properly Identify “Unusual” Hepatitis C Virus Subtypes Resistant to Direct-Acting Antiviral Drugs in The Gambia

2025/07/19 by Erwan Vo Quang, Christophe Rodriguez, Arnaud Ly +9 · 1 voice
Medicine · #Hepatitis C virus research #HIV/AIDS drug development and treatment #Systemic Lupus Erythematosus Research

paper · doi:10.1093/infdis/jiaf378

openalex publication_date 2025/07/19 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Abstract

We evaluated the ability of the commercial Sentosa SQ Hepatitis C Virus Genotyping Assay to identify the hepatitis C virus (HCV) genotype subtype in patients from The Gambia. Subtype was determined from the Sentosa-generated NS5B sequences using 3 bioanalytical methods: Sentosa SQ HCV Genotyping Assay bioanalytical tool, Geno2pheno, and the National Reference Center in-house method. The Sentosa assay result agreed with the reference method in only 2 of 13 cases. This study highlights the difficulty of correctly identifying HCV subtypes in a region of Africa with a high diversity of HCV genotype 1 and 2 subtypes that may be resistant to antivirals.

Citations

• ‘Unusual’ HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment

Discussions

• Virological tools fail to properly identify "unusual" hepatitis C virus subtypes resistant to direct-acting antiviral drugs in The Gambia ✅ Just Accepted #IDSky [bsky, 1 points, 0 comments]

Related

• Highly genetically diverse variants of hepatitis C virus still predominate in Cameroon but with low frequency of mutations associated to resistance of NS5B polymerase-targeted antivirals
• ‘Unusual’ HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment
• A Study to Assess the Efficacy of the Sofosbuvir/Daclatasvir Combination as a Pan-genotypic Treatment for Hepatitis C without HCV Genotype Determination
• Hyperendemicity and genotype diversity of hepatitis B virus among patients attending the University of Abuja Teaching Hospital, Nigeria
• Eligibility for hepatitis B virus (HBV) treatment and prevalence of drug resistance in a Ugandan population cohort